Verseon Expands the Chemical Frontiers of Drug Discovery with DQM and VersAI

Written by

in

Verseon uses quantum mechanics models through its DQM platform to design new drug molecules and combines them with VersAI to generate candidate variants, which are tested in the laboratory and advanced to clinical trials. Existing methods can treat only 500 of the approximately 10,000 known human diseases. In peer-reviewed research, its oral anticoagulants, known as PROACs, were shown to prevent blood clot formation while preserving natural blood-stopping ability.

Source:Nano Magazine – Latest Nanotechnology News · Read Original

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *